Race Oncology (ASX:RAC) Institutional Ownership : 0.03% (As of Apr. 12, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Race Oncology Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Race Oncology's institutional ownership is 0.03%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Race Oncology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Race Oncology's Float Percentage Of Total Shares Outstanding is 0.00%.

Race Oncology Institutional Ownership Historical Data

The historical data trend for Race Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Race Oncology Institutional Ownership Chart

Race Oncology Historical Data

The historical data trend for Race Oncology can be seen below:

	2021-01-31	2021-02-28	2021-03-31	2021-04-30	2021-05-31	2021-06-30	2021-07-31	2021-08-31
Institutional Ownership	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.03

Race Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Race Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000

Website

https://www.raceoncology.com

Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.

Race Oncology Headlines

No Headlines